<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01384110</url>
  </required_header>
  <id_info>
    <org_study_id>2010-RD-01-CLN</org_study_id>
    <nct_id>NCT01384110</nct_id>
  </id_info>
  <brief_title>Efficacy of a Brown Seaweed Extract Rich in Polyphenols on Glycemic Response to Sucrose in Human</brief_title>
  <official_title>Efficacy of a Brown Seaweed Extract Rich in Polyphenols on Glycemic Response to Sucrose in Human</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>innoVactiv Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>innoVactiv Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary endpoint of this trial will be to evaluate if a single administration in human of
      a lemon ice tea containing 500 mg of a polyphenol-rich algal powder is able to reduce
      postprandial glycemia and insulinemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Significant reduction in postprandial glycemia</measure>
    <time_frame>Immediately after product administration (single use)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Significant reduction in postprandial insulinemia</measure>
    <time_frame>Immediately after product administration (single use)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>First administration up to 7 days after last administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Hyperglycemia</condition>
  <arm_group>
    <arm_group_label>Brown Seaweed Lemon Tea</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration of lemon tea containing 500 mg of brown seaweed powder and 50 g of sucrose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo lemon tea</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single administration of placebo lemon tea containing 50 g of sucrose</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Reduction of glycemic index of ingested foods</intervention_name>
    <description>Oral administration of the experimental lemon tea powder(56.1 g) and the placebo lemon tea powder (55.6 g) dissolved in water. Each participant will receive both treatment in a cross-over protocol design during 2 visits separated by a 2-weeks period. The day before both intervention, participants will consume a standardised meal for the supper.</description>
    <arm_group_label>Brown Seaweed Lemon Tea</arm_group_label>
    <arm_group_label>Placebo lemon tea</arm_group_label>
    <other_name>InSea2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteer aged 18 to 60

          -  BMI between 20 and 30

          -  Non-smoking

          -  Using valid contraceptive method (women of childbearing age)

        Exclusion Criteria:

          -  Iodine allergy, or allergy to components of the test product or placebo or standard
             meal

          -  Diabetes

          -  Use of dietary supplements for duration of study

          -  History of gastro-intestinal affections, anemia, major surgeries or surgeries of the
             stomach or digestive tract
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Couture, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut des nutraceutiques et des aliments fonctionnels</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut des Nutraceutiques et des Aliments Fonctionnels (INAF)</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2011</study_first_submitted>
  <study_first_submitted_qc>June 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2011</study_first_posted>
  <last_update_submitted>November 14, 2011</last_update_submitted>
  <last_update_submitted_qc>November 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amylase</keyword>
  <keyword>Glucosidase</keyword>
  <keyword>Glycemic response</keyword>
  <keyword>Sucrose</keyword>
  <keyword>Seaweed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

